Cantor Fitzgerald upgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a neutral rating to an overweight rating in a research report sent to investors on Wednesday, BenzingaRatingsTable reports. They currently have $20.00 price target on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on DVAX. Zacks Investment Research raised shares of Gerdau from a sell rating to a hold rating in a research report on Monday, May 13th. BidaskClub raised shares of Xilinx from a hold rating to a buy rating in a research report on Saturday, June 29th. Cowen reissued a buy rating on shares of Odonate Therapeutics in a research report on Monday, June 3rd. William Blair reissued a buy rating on shares of Dynavax Technologies in a research report on Friday, June 21st. Finally, ValuEngine downgraded shares of Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $16.81.

NASDAQ:DVAX opened at $4.03 on Wednesday. Dynavax Technologies has a twelve month low of $3.57 and a twelve month high of $16.15. The company has a current ratio of 5.27, a quick ratio of 4.61 and a debt-to-equity ratio of 4.88. The stock’s 50 day moving average is $4.25.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.05. The company had revenue of $5.77 million for the quarter, compared to the consensus estimate of $5.95 million. Dynavax Technologies had a negative net margin of 1,156.11% and a negative return on equity of 190.84%. Dynavax Technologies’s revenue was up 3294.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.63) EPS. On average, equities research analysts expect that Dynavax Technologies will post -2.13 earnings per share for the current year.

In other news, SVP Robert Coffman sold 32,218 shares of the company’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $4.58, for a total value of $147,558.44. Following the sale, the senior vice president now directly owns 132,470 shares of the company’s stock, valued at approximately $606,712.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.90% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. Advisor Group Inc. boosted its holdings in shares of Dynavax Technologies by 515.3% in the 4th quarter. Advisor Group Inc. now owns 4,473 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 3,746 shares during the last quarter. Quantamental Technologies LLC acquired a new position in shares of Dynavax Technologies in the 1st quarter valued at $62,000. BNP Paribas Arbitrage SA lifted its stake in shares of Dynavax Technologies by 56,326.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 12,978 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 12,955 shares during the period. Pearl River Capital LLC acquired a new position in shares of Dynavax Technologies in the 1st quarter valued at $106,000. Finally, Legal & General Group Plc lifted its stake in shares of Dynavax Technologies by 18.7% in the 4th quarter. Legal & General Group Plc now owns 11,814 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 1,860 shares during the period. 81.94% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Further Reading: Return on Investment (ROI)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.